Nigel Davies

Principal Scientist, Advanced Drug Delivery at AstraZeneca

Speaker

Nigel joined AZ in 2008 as a Senior Scientist in biopharmaceutics in Pharmaceutical Development (Göteborg) having responsibilities for a number of clinical and life-cycle management projects, notably late stage/regulatory submissions of Vimovo, Forxiga, Kombi/Komboglyze IR & XR, Xigduo IR & XR and Nexium OTC.

Since transitioning to the Advanced Drug Delivery group in the Innovative Medicine Early Development function in 2014, Nigel has pioneered AstraZeneca’s efforts into the delivery of mRNA therapeutics as well as oral delivery of macromolecules resulting in a number of assets progressing from early pre-clinical evaluation to CDID (and even clinical testing).

Before joining AstraZeneca, Nigel had almost 20 years tenure in academia at Universities in New Zealand and Australia, leading research groups focusing on developing novel delivery systems for macromolecules. Over the years, Nigel has published over 70 articles in peer-reviewed journals, has supervised to completion 18 PhD students and is regularly invited to give talks at high profile conferences.

Nigel continues to provide depth and breadth to the scientific input impacting the wider project portfolio as well as striving to identify and develop novel systems (both internally and via external collaborations) to overcome the challenges associated with the delivery of macromolecules in order to advance AZ’s New Modalities portfolio.